JP6997760B2 - Ｄｐｐ－ｉｖ長時間作用型阻害剤の結晶及びその塩 - Google Patents

Ｄｐｐ－ｉｖ長時間作用型阻害剤の結晶及びその塩 Download PDF

Info

Publication number
JP6997760B2
JP6997760B2 JP2019506673A JP2019506673A JP6997760B2 JP 6997760 B2 JP6997760 B2 JP 6997760B2 JP 2019506673 A JP2019506673 A JP 2019506673A JP 2019506673 A JP2019506673 A JP 2019506673A JP 6997760 B2 JP6997760 B2 JP 6997760B2
Authority
JP
Japan
Prior art keywords
crystal
formula
compound represented
phosphate
crystal composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019506673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527708A5 (enExample
JP2019527708A (ja
Inventor
桑光明
劉林
張愛明
喬家彬
郭暁鵬
張喜全
夏春光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2019527708A publication Critical patent/JP2019527708A/ja
Publication of JP2019527708A5 publication Critical patent/JP2019527708A5/ja
Application granted granted Critical
Publication of JP6997760B2 publication Critical patent/JP6997760B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019506673A 2016-08-12 2017-08-11 Ｄｐｐ－ｉｖ長時間作用型阻害剤の結晶及びその塩 Expired - Fee Related JP6997760B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610665625.9 2016-08-12
CN201610666564 2016-08-12
CN201610665625 2016-08-12
CN201610666564.8 2016-08-12
PCT/CN2017/097046 WO2018028666A1 (zh) 2016-08-12 2017-08-11 Dpp-iv长效抑制剂的结晶及其盐

Publications (3)

Publication Number Publication Date
JP2019527708A JP2019527708A (ja) 2019-10-03
JP2019527708A5 JP2019527708A5 (enExample) 2020-09-24
JP6997760B2 true JP6997760B2 (ja) 2022-01-18

Family

ID=61162770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019506673A Expired - Fee Related JP6997760B2 (ja) 2016-08-12 2017-08-11 Ｄｐｐ－ｉｖ長時間作用型阻害剤の結晶及びその塩

Country Status (9)

Country Link
US (1) US10822319B2 (enExample)
EP (1) EP3498704A4 (enExample)
JP (1) JP6997760B2 (enExample)
KR (1) KR20190039754A (enExample)
CN (1) CN109874304B (enExample)
AU (1) AU2017308691B2 (enExample)
CA (1) CA3033890A1 (enExample)
RU (1) RU2753335C9 (enExample)
WO (1) WO2018028666A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108456196A (zh) * 2017-02-22 2018-08-28 四川科伦博泰生物医药股份有限公司 3-氨基四氢吡喃衍生物的盐及其多晶型、其制备方法和用途
CN111793071B (zh) * 2020-07-06 2021-06-04 四川凯科医药科技有限公司 奥格列汀的合成工艺

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009526848A (ja) 2006-02-15 2009-07-23 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしてのアミノテトラヒドロピラン
JP2012508746A (ja) 2008-11-13 2012-04-12 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としてのアミノテトラヒドロピラン
JP2014518266A (ja) 2011-06-29 2014-07-28 メルク・シャープ・アンド・ドーム・コーポレーション ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形
WO2015031228A1 (en) 2013-08-30 2015-03-05 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041016A2 (en) * 1999-12-02 2001-06-07 General Electric Company System and method for valuing loan portfolios using fuzzy clustering
CN105985357A (zh) * 2015-02-12 2016-10-05 北京赛林泰医药技术有限公司 取代的氨基六元饱和杂脂环类长效dpp-iv抑制剂
WO2017031918A1 (zh) 2015-08-24 2017-03-02 四川科伦药物研究院有限公司 长效二肽基肽酶-iv抑制剂、用途及其中间体的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009526848A (ja) 2006-02-15 2009-07-23 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしてのアミノテトラヒドロピラン
JP2012508746A (ja) 2008-11-13 2012-04-12 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としてのアミノテトラヒドロピラン
JP2014518266A (ja) 2011-06-29 2014-07-28 メルク・シャープ・アンド・ドーム・コーポレーション ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形
WO2015031228A1 (en) 2013-08-30 2015-03-05 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Pharmaceutical Sciences，1977年，Vol.66, No.1，p.1-19
小嶌隆史，医薬品開発における結晶性選択の効率化を目指して，薬剤学，2008年09月01日，Vol.68, No.5，p.344-349

Also Published As

Publication number Publication date
RU2019105352A3 (enExample) 2020-12-17
EP3498704A4 (en) 2020-03-04
RU2753335C9 (ru) 2021-09-20
CA3033890A1 (en) 2018-02-15
US10822319B2 (en) 2020-11-03
WO2018028666A1 (zh) 2018-02-15
AU2017308691A1 (en) 2019-03-28
US20190284153A1 (en) 2019-09-19
EP3498704A1 (en) 2019-06-19
RU2019105352A (ru) 2020-09-14
KR20190039754A (ko) 2019-04-15
AU2017308691B2 (en) 2021-12-16
JP2019527708A (ja) 2019-10-03
CN109874304B (zh) 2021-06-25
RU2753335C2 (ru) 2021-08-13
CN109874304A (zh) 2019-06-11

Similar Documents

Publication Publication Date Title
TWI815396B (zh) 具有病毒增殖抑制作用之三嗪衍生物及含有其等之醫藥組合物
US8933114B2 (en) Polymorphic forms of asenapine maleate and processes for their preparation
KR20170033684A (ko) 리나글립틴 결정형 및 이의 제조방법
TW202124373A (zh) 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法
KR20110120941A (ko) 결정 다형성 형태 631
JP6997760B2 (ja) Ｄｐｐ－ｉｖ長時間作用型阻害剤の結晶及びその塩
CN102241726B (zh) 甘草次酸衍生物及其作为抗肿瘤药物的应用
CN111689958B (zh) 磷酸二酯酶抑制剂的晶型、其制备方法及其用途
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
TWI333856B (en) Crystals of taxane and process for their production
EP2751094B1 (en) Novel crystal form
US8993602B2 (en) Benzoic acid salt of otamixaban
US10221185B2 (en) Crystal form of substituted aminopyran derivativek
CN103626845B (zh) 作为糖原磷酸化酶抑制剂的芳基并吡咯-2-甲酰胺二肽衍生物、其制备方法及医药用途
KR20240094023A (ko) S1p1 수용체 작용제의 부가 염 및 이의 결정 형태 및 약제학적 조성물
JP2024522836A (ja) ピリミジン系誘導体の結晶形およびその製造方法
KR20060011997A (ko) 벤즈이미다졸 유도체의 결정 및 이의 제조 방법
CN110128359B (zh) 一种尿酸转运体1抑制剂的晶体及其制备方法和用途
CN115141136A (zh) 特考韦瑞药的共晶及其制备方法
HK40002160B (zh) Dpp-iv长效抑制剂的结晶及其盐
CN119841853A (zh) 一种嘧啶甲酰胺类化合物的晶型及其制备方法
CN116396305A (zh) 一种稠环衍生物的晶型、其制备方法及其应用
CN118666758A (zh) 一种抗黑色素瘤的苄基嘧啶类化合物及其制备方法和应用
WO2022198361A1 (zh) 一种达比加群酯乙酯盐酸盐新晶型及其制备方法和应用
HK40035594A (en) Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211217

R150 Certificate of patent or registration of utility model

Ref document number: 6997760

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees